Replies to post #407531 on Amarin Corp Plc (AMRN)

[ziploc_1]

Vascepa plus MND-2119 would be patent protected in the U.S. and could be marketed under the name ANTI-CVD...This new product could be priced about the same as Vascepa, with Amarin absorbing the price of the statin.

it should not be difficult to get FDA approval for the drug.